The kind of stroke people do not see coming

Most people picture a stroke as a clot. A vessel blocks, part of the brain starves, a face droops. That is the common kind.

A subarachnoid haemorrhage is different. A blood vessel on the surface of the brain bursts, usually a weak bulge called an aneurysm, and blood floods the thin space between the brain and the membranes that wrap it. People who survive one often describe it as the worst headache of their life, arriving in seconds.

The paper this series is built on opens with a blunt line about it. Diagnosis and surgery have improved a great deal, yet effective treatments remain limited and outcomes are still poor. Fixing the burst vessel is one job. Saving the brain tissue around it is another, and that second job is where medicine keeps coming up short.

The shift that changed the research

For decades, doctors blamed most of the damage on something that happens days later. The arteries around the bleed clamp down, called vasospasm, and the brain is starved of blood a second time.

So researchers went after vasospasm. And here is the twist the authors point out: reducing vasospasm did not improve long-term outcomes. Patients still did badly.

That forced a rethink. Attention moved to what happens in the first 72 hours after the bleed, a window now called early brain injury. The paper cites work suggesting that early brain injury, not the later spasm, is the dominant cause of death after this kind of bleed. If that is right, the treatment window is the first three days, and the target is whatever is killing brain cells during them.

That is where the title of this series comes from.

Why mitochondria keep coming up

Inside almost every cell are mitochondria, the small structures that turn food and oxygen into usable energy. They are also the main source of reactive oxygen species, the unstable molecules that damage proteins, fats and DNA when they get out of hand.

After a brain bleed, the authors argue, damaged mitochondria start leaking those molecules. The damage builds. At a certain point the mitochondria release signals that tell the cell to dismantle itself, a tidy form of cell death called apoptosis. Do that to enough neurons and you lose function.

So if you could protect mitochondria during that 72 hour window, you might save cells that would otherwise die. That is the logic behind testing SS-31.

Enter SS-31

SS-31 is a short peptide, just four amino acids long, designed to get into cells and settle on the inner membrane of mitochondria. You will also see it called elamipretide. The paper describes it as a mitochondria-targeted antioxidant that can soak up excess reactive oxygen species, limit fat damage in cell membranes and reduce mitochondrial swelling.

Before this study, SS-31 had already been tested in animal models of Huntington's disease, ALS, diabetic damage to the retina and Alzheimer's disease. What nobody had done, according to the authors, was test it after a subarachnoid haemorrhage.

So a team at the First Affiliated Hospital of Hainan Medical University in Haikou, China, set out to do exactly that, in rats.

What they measured

Here is the short version of the study design, which we will unpack properly in later parts.

The team gave rats a controlled bleed around the base of the brain. Thirty minutes later, some rats got SS-31 by injection and some got a dummy solution. Then they measured:

  • How well the rats ate, moved and walked
  • How swollen their brains were
  • How leaky the barrier between blood and brain had become
  • How many neurons were dying
  • Which death signals were switched on inside the cells
  • How much oxidative damage had built up, and how the cell's own antioxidant enzymes were holding up

On almost every one of those measures, the SS-31 rats did better than the untreated ones.

Why this paper is worth eight parts

It would be easy to write one paragraph saying "peptide protects rat brains" and move on. That would miss the interesting parts.

There is a dose result that does not behave the way people assume doses behave. There is a clean chain of evidence from the cell's power supply all the way to whether a rat finishes its dinner. And there are some numbers in the paper that do not line up, which I will lay out plainly in the final part, because a series that only cheers is an advert.

Over the next seven parts we will go through what SS-31 is, how you model a brain bleed in a rat, the dose puzzle, brain swelling and the blood-brain barrier, how you count dying neurons, what oxidative stress really means, and finally where the paper is weak.

One thing to hold on to from the start: this is a rat study. It tells us something real about biology. It does not tell us what SS-31 does in a person who has just had a bleed. Keep that line clear and the rest of the series will make a lot more sense.

This series discusses a peer-reviewed laboratory study in rats. The results have not been shown in people. Nothing here is medical advice, and SS-31 is discussed for research purposes only.